Edwards Lifesciences (EW) PT Lowered to $114 at Stifel, 'Buy' Kept
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
BTIG Sets New PT of $100 on Edwards Lifesciences (EW); Reports Slight Q3 Miss Amid Lofty Expectations
October 26, 2016 8:57 AM EDTBTIG affirms Edwards Lifesciences (NYSE: EW) with a Buy rating and sets a price target of $110 on the stock following Q3 results.
The firm commented today: Expectations were lofty after multiple beats including Q2 THVs that blew away expectations. We and most others... More
Edwards Lifesciences (EW): TAVR Miss Drives PT Cut - Jefferies
October 26, 2016 7:11 AM EDTJefferies analyst, Raj Denhoy, reiterated his Buy rating on shares of Edwards Lifesciences (NYSE: EW) and cut his price target to $115 from $125 after 3Q saw a $15mn TAVR miss, most pronounced in the EU, but the US was also light.
The... More
Edwards Lifesciences (EW) Reports In-Line Q3 EPS
October 25, 2016 4:17 PM EDTEdwards Lifesciences (NYSE: EW) reported Q3 EPS of $0.68, in-line with the analyst estimate of $0.68. Revenue for the quarter came in at $739.4 million versus the consensus estimate of $749.14 million.
GUIDANCE:
Edwards Lifesciences sees Q4 2016 EPS of $0.67-$0.77, versus the consensus of $0.74.... More
